ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025
CellPhenoX: An Explainable Machine Learning Method for Identifying Cell Phenotypes To Predict Clinical Outcomes from Single-Cell Multi-Omics.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Cancer Heterogeneity and Cancer Cell Plasticity: Molecular Mechanisms and Precision Therapy.MedComm · 2026Review
- Microbiome-Driven Risk Stratification and Biotherapeutics in Radiation Enteritis.Computational and structural biotechnology journal · 2026Review
- CellPhenoX: An Explainable Machine Learning Method for Identifying Cell Phenotypes To Predict Clinical Outcomes from Single-Cell Multi-Omics.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Immune Cell Dynamics in Cardiac Diseases: Insights From Single-Cell Sequencing.Journal of cellular and molecular medicine · 2025Review
- Role of Bioinformatics in Identifying Novel Biomarkers for Immune Cell Exhaustion and Tumor Microenvironment.Technology in cancer research & treatmentReview
Corrections and comments
- Update of
Authors and funding
5 authors.
Funding
Abstract
Single-cell technologies have transformed the understanding of disease heterogeneity, but linking cell-level phenotypic alterations to clinical outcomes becomes increasingly challenging as single-cell datasets continue to expand. This is further complicated by the lack of interpretability in existing methods and the difficulty of detecting interaction effects-nonlinear dependencies between factors like sex, age, and disease. To address this, a novel explainable machine learning method, CellPhenoX, is developed to identify cell-specific phenotypes and interaction effects linked to clinical outcomes. CellPhenoX integrates classification models, explainable artificial intelligence (AI) techniques, and a statistical framework to generate interpretable, cell-specific scores to uncover condition-associated cell populations. Extensive benchmarking and applications demonstrate the efficacy of CellPhenoX across diverse single-cell study designs, including the dedicated and disease-motivated simulations, binary disease-control comparisons, and severity-stratified patient cohorts. Notably, CellPhenoX identifies an activated monocyte phenotype in COVID-19, with expansion correlated with disease severity after adjusting for covariates and interactive effects. It also uncovers a fibroblast-specific state transition gradient predicting tissue inflammation in chronic diseases, and identifies therapy-induced T cell changes and biomarkers linked to the tumor microenvironment. By integrating interpretability into clinical classification, CellPhenoX offers a powerful framework for translating single-cell findings into clinical impact.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.